Novartis AG logo

NOVN - Novartis AG News Story

CHF80.15 -0.3  -0.4%

Last Trade - 4:35pm

Sector
Healthcare
Size
Large Cap
Market Cap £142.27bn
Enterprise Value £166.24bn
Revenue £35.39bn
Position in Universe 4th / 1053

Novartis agrees to make ingredients Roche's Actemra for COVID-19 patients

Thu 15th April, 2021 6:44am
ZURICH, April 15 (Reuters) - Swiss drugmaker Novartis
 NOVN.S  has signed a deal to make ingredients for Roche's
 ROG.S  Actemra treatment that is being repurposed for people
with COVID-19, the company said on Thursday.
    The arrangement is the third transaction signed by Novartis
following agreements with BioNTech  22UAy.DE  and CureVac
 5CV.DE  to make therapies for other firms to help fight the
pandemic.
    Actemra is a treatment for rheumatoid arthritis which is
also being tested in various clinical trials to treat COVID-19
associated pneumonia.
    Novartis will make the active pharmaceutical ingredients for
the drug at its Singapore site, which will get the necessary
technology and expertise during the second quarter of this year.
    "Novartis is fully committed to collaborating with Roche in
offering our proven biologics production capabilities," said
Steffen Lang, Head of Novartis Technical Operations.
    "As one of the world's largest producers of medicines,
Novartis can mobilize its manufacturing capabilities on multiple
fronts."
    In March, Novartis signed a deal with CureVac to produce
material for its COVID-19 candidate drug at its site in Kundl,
Austria. The Swiss company also signed a deal with BioNtech to
provide manufacturing capacity for a COVID-19 vaccination at its
plant in Stein, Switzerland.

 (Reporting by John Miller, writing by John Revill; editing by
Brenna Hughes Neghaiwi)
 ((John.Revill@thomsonreuters.com; +41 58306 7022; Reuters
Messaging: john.revill.thomsonreuters.com@reuters.net))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.